Medpace Holdings (MEDP) Cash & Equivalents (2015 - 2026)

Medpace Holdings has reported Cash & Equivalents for 12 years, with the latest figure at $652.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 47.85% year-over-year to $652.7 million; the trailing twelve-month figure through Mar 2026 stood at $652.7 million (up 47.85% YoY), and the FY2025 full-year result was $497.0 million, down 25.75% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $652.7 million, up from $497.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $669.4 million in Q4 2024, with the low at $28.3 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $281.1 million across 5 years, with a median of $245.4 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 93.87% — and 2024, when it jumped 1205.37%.
• Medpace Holdings' Cash & Equivalents stood at $28.3 million in 2022, then jumped by 768.38% to $245.4 million in 2023, then jumped by 172.74% to $669.4 million in 2024, then dropped by 25.75% to $497.0 million in 2025, then soared by 31.31% to $652.7 million in 2026.
• The last three Cash & Equivalents figures came in at $652.7 million (Q1 2026), $497.0 million (Q4 2025), and $285.4 million (Q3 2025), per Business Quant data.